Eric Venker Sells 177,704 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 177,704 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $11.54, for a total value of $2,050,704.16. Following the transaction, the chief operating officer now owns 740,976 shares in the company, valued at approximately $8,550,863.04. This trade represents a 19.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Eric Venker also recently made the following trade(s):

• On Friday, December 27th, Eric Venker sold 176,900 shares of Roivant Sciences stock. The stock was sold at an average price of $11.82, for a total value of $2,090,958.00.
• On Friday, December 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00.
• On Wednesday, November 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00.
• On Monday, October 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $11.65, for a total value of $1,165,000.00.

Roivant Sciences Trading Up 3.5 %

NASDAQ ROIV opened at $11.83 on Thursday. The business’s 50-day moving average price is $11.91 and its two-hundred day moving average price is $11.55. Roivant Sciences Ltd. has a 12 month low of $9.69 and a 12 month high of $13.06. The firm has a market capitalization of $8.61 billion, a PE ratio of 2.09 and a beta of 1.25.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors have recently made changes to their positions in the stock. Clearbridge Investments LLC grew its position in shares of Roivant Sciences by 51.3% in the 2nd quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock valued at $19,666,000 after buying an additional 630,712 shares during the last quarter. Point72 Asset Management L.P. grew its position in shares of Roivant Sciences by 40.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock valued at $6,840,000 after buying an additional 185,226 shares during the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $2,267,000. TOMS Capital Investment Management LP bought a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $46,333,000. Finally, Barclays PLC grew its position in shares of Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after buying an additional 75,609 shares during the last quarter. Institutional investors own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ROIV. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Bank of America boosted their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.93.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.